Every 8-K that Conexeu Sciences Inc. (CNXU) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow CNXU and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full CNXU filings page.
Conexeu Sciences Inc. (CNXU) reported a series of unregistered equity issuances from June 18, 2026 through September 4, 2026 that in aggregate exceeded 5% of its outstanding common stock, triggering disclosure under Item 3.02. Over this period, the company issued 1,448,368 unregistered shares of common stock and 202,500 unregistered common stock purchase warrants under various consulting, marketing, director, and warrant exercise arrangements.
The largest single transaction occurred on September 4, 2026, when Conexeu issued 762,608 shares upon warrant exercises at $2.30 per share for $1,753,998.40 in gross proceeds, which it intends to use for working capital and general corporate purposes. Additional issuances included cashless and low‑priced warrant exercises and share grants to consultants and directors at deemed prices between $0.001 and $13.96 per share. All securities were issued as "restricted securities" in reliance on private offering exemptions, primarily Rule 506(b) of Regulation D, Section 4(a)(2), and Rule 903(b) of Regulation S.
Conexeu Sciences has completed its 12‑month preclinical P.R.O.O.F (Performance and Regeneration Outcomes of Flowable Collagen) study for the CXU™ tissue‑restoration platform. In animal models, the study met objectives for facial cheek tissue restoration, a large‑volume 200cc‑equivalent model, and injectable performance benchmarks such as injectability and volumizing behavior.
The company emphasizes that CXU™ and Ten‑Minute Tissue™ remain investigational, with no regulatory clearance or commercial launch. Conexeu plans a predicate‑based 510(k) submission for a lead wound‑care device in Q1 2027, targeting a 90‑day FDA review as a first step before pursuing medical aesthetics and other soft‑tissue indications.
Conexeu Sciences Inc. reported the cash exercise of common stock purchase warrants and related share issuances. On June 4, 2026, the company issued 416,667 common shares for gross proceeds of about $166,667 under a warrant exercise incentive program and granted 416,667 new Incentive Warrants.
The Incentive Warrants allow holders to buy one additional share each at $2.30 for 36 months. After this exercise, 410,338 Program Warrants remained outstanding and common shares outstanding were 26,658,330. On June 8, 2026, Conexeu issued 100,000 Performance Warrant Shares at $0.001 per share, raising $100 and bringing total common shares outstanding to 26,758,330.